The City of Hope Medical Center is conducting a Phase 2 clinical trial to evaluate the safety and efficacy of islet cell transplantation in patients with type 1 diabetes using a T-cell depleting immunosuppression regimen. The target market includes patients suffering from severe complications of type 1 diabetes, particularly those with unstable blood glucose control and hypoglycemia unawareness. The potential to improve patient quality of life and reduce insulin dependency positions this therapy favorably against existing diabetes management options. The competitive landscape includes other immunosuppressive strategies and emerging diabetes therapies, necessitating a thorough diligence process to assess market entry and reimbursement pathways.